Soham D. Puvvada MD

Assistant Professor of Medicine, Lymphoma.
Division of Hematology-Oncology.

E-Mail Address: 
Phone Number: 
520-626-6515
Patient Appointments: 
520-694-2873
Short Bio: 

Dr. Puvvada is a faculty physician who specializes in the treatment of lymphoid malignancies including but not limited to Hodgkins Lymphoma, Non-Hodgkins Lymphoma and Chronic Lymphocytic leukemia. She is a clinical translational researcher who designs novel investigator initiated trials that bring  exciting concepts from the bench to the bedside.

Dr. Puvvada believes in balance and in her free time she loves cooking, and biking.

Clinical Information
Specialty: 
Medical Oncologist
Clinical Practice Sites: 
The University of Arizona Cancer Center - North Campus
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Member
Summary of Research Activity: 

1. A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199
• AbbVie:  M13-364
• PI:  Soham D. Puvvada MD

2. An Extension Study of ABT-199 in Subjects with Advanced Lymphoproliferative Diseases
• AbbVie:  M13-835
• PI:  Soham D. Puvvada MD

3. A Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the17p Deletion
• AbbVie:  M13-982
• PI:  Soham D. Puvvada MD

4. A Phase II, Open-Label Study of Bortezomib (Velcade®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas. Investigator initiated trial.
• Millennium: X05260 / IRB 12-0288-04
• PI:  Soham D. Puvvada MD

5.  A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma (stage 1).
Investigator initiated trial.
• Spectrum: IRB 12-0288-04
• PI:  Soham D. Puvvada MD

6. A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine.
• Millennium: #C14011 / WIRB #20110910
• PI: Soham D. Puvvada MD.

7.      A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with       
Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
AbbVie M12-175
• PI: Soham D. Puvvada MD.

8. Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia
• AVL-292-003
• PI: Thomas P. Miller MD
• Co-PI: Soham D. Puvvada, MD

9. SWOG 0801: A Phase II Study of Iodine-131 Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin’s Lymphoma
• PI: Thomas P. Miller, MD
• Co-PI: Soham D. Puvvada MD

10. Phase II Trial of Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin's Lymphoma
Investigator initiated trial.
• Spectrum (transferred from Biogen Idec): IRB 05-0303-04 / 106-P158  
• PI: Thomas P. Miller MD
• Co-PI:  Soham D. Puvvada MD

11. SWOG 0816: A Phase II Trial of Response Adapted Therapy of Stage III-lV Hodgkin Lymphoma Using Early Interim FDGPET Imaging
• PI: Thomas P. Miller, MD
• Co-PI: Soham D. Puvvada MD

12. SWOG 1001 A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
• PI: Thomas P. Miller, MD
• Co-PI: Soham D. Puvvada MD

13. SWOG 0806 A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
• PI: Thomas P. Miller, MD
• Co-PI: Soham D. Puvvada MD

14. CALGB 50604 Phase II Trial of Response- Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
• PI: Thomas P. Miller, MD
• Co-PI: Soham D. Puvvada MD
 

Selected Publications: 

• Puvvada SD et al.  Prognostic implication of NF-κB and BCL3 activation in metastatic colorectal cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstract 11090).

• Tyler W Buckner, Soham Puvvada, Chirag Amin, and Nigel S. Key Differing Clot Distribution in Black Compared to White Patients Presenting with Acute Lower Extremity Deep Venous Thrombosis. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3819.

• Puvvada SD et al.  NF-kB and Bcl-3 Activation Are Prognostic in Metastatic Colorectal Cancer. Oncology 2010; 78(3-4) 181-8. doi:  10.1159/000313697.  Epub 2010 Apr 23 PMID 20414006  PMCID  PMC2914399

• Puvvada Soham et al.  Selective IKKβ Inhibition of the NF-Kappab Pathway Is An Effective Therapeutic Strategy In Lymphomas. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 1849

• Puvvada SD, et al. Emerging Frontiers in Therapeutics of Diffuse Large B cell Lymphoma: Epigenetics and B cell Receptor Signaling. J Cancer Therapy 2013 Jan 28, Journal ID 8901557

• Puvvada SD, et al.  Molecular Classification, Pathway Addiction, and Therapeutic Targeting in Diffuse Large B cell Lymphoma. Cancer Genetics 2013 Jan 30, PMCID 24080457

• Schatz JH, Puvvada SD, Oricchio E, Wendel HG.  Progress Against Follicular Lymphoma. Curr Opin Hematol. 2013 May 13. [Epub ahead of print] PMCID: 23673338

• Puvvada S, Miller T. Radiotherapy is not essential to Cure Diffuse Large B-cell Non-Hodgkin Lymphoma. Oncology, 2013 May Supplement.

• Soham Puvvada, Daniel Persky, Lora Inclan, Jonathan Schatz, Ellen Chase, Jose  M Guillen-Rodriguez, Denise J  Roe, Thomas Miller. Yttrium-90-Ibritumomab tiuxetan (Zevalin) radioimmunotherapy after cytoreduction with ESHAP chemotherapy in patients with relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results of a phase II study. ASH, December 2013 #4404

• Kevin R. Kelly, Daniel O. Persky, Daruka Mahadevan, Thomas P. Miller, Soham D. Puvvada,  Kevin McDonagh, John Hayslip, Steven I. Park, Jia Ruan, Peter J. Rosen, Swaminathan Padmanabhan Iyer, Alexandra Stefanovic, Bin Zhang, Xiaofei Zhou, Claudio Dansky Ullmann, E. Jane Leonard, Jonathan W. Friedberg. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. ASH, December 2013 #3027

• Paul M. Barr, Margaret M. Briehl, Steven H Bernstein, Jonathan W. Friedberg, Andrea Baran, Derick R. Peterson, Daniel Oscar Persky, Carla Casulo, Megan M. Herr, Jamie Littleton, Erin Cebula, Mark Schwartz, Soham D. Puvvada, Robert T Dorr, Richard I Fisher, Thomas P. Miller. Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study. ASH, December 2013 #89

• Lingxiao Li, Praechompoo Pongtornpipat, Soham D. Puvvada, Jonathan H. Schatz. Targeting MYC Expression with CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphoma. ASH, December 2013 #1831

• Soham Puvvada & Sandy Kurtin. Toxicity of targeted therapeutic agents in lymphoma and management: Part1: monoclonal antibodies and radioimmunotherapy. Int. J. Hematol. Oncol. (2014) 3(1), 1-11. manuscript in press.

Bio sketch: 
Professional Information
Board Certifications: 

Medical Oncology

Hematology

Internal Medicine

Professional Affiliations: 

2012 - Member, Southwest Oncology Group.
2009 - Member, American Society of Clinical Oncology.
2009 - Member, American Society of Hematology.
2002 - Member, American College of Physicians.
2002 - Member, American Medical Association.

Honors: 

2014: NIH Certification in Principles and Practices of Clinical Research
2013: SWOG Young Investigator Award.
2013: Coltman Fellowship Award, The Hope Foundation.
2012: Robert Silber Memorial Research Award, Duke University

Academic Information
Fellowship: 
Duke University Medical Center
Residency: 
University of North Carolina
Medical School: 
University of South Florida College of Medicine